Shandong Pharmaceutical Glass Co Ltd Capital Reinvestment Ratio
Shandong Pharmaceutical Glass Co Ltd capital reinvestment ratio. Shandong Pharmaceutical Glass Co Ltd (600529) has a Capital Reinvestment Ratio of 3.69x as of December 2025, meaning it reinvests 4% of its operating cash flow (CN¥41.46 Million) in capital expenditures (CN¥153.18 Million). Check Shandong Pharmaceutical Glass Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Shandong Pharmaceutical Glass Co Ltd (2001–2025)
Capital reinvestment ratio of Shandong Pharmaceutical Glass Co Ltd from 2001 to 2025. This chart tracks Shandong Pharmaceutical Glass Co Ltd's Capital Reinvestment Ratio across 24 annual periods. Also explore Shandong Pharmaceutical Glass Co Ltd (600529) equity growth momentum to track the company's year-over-year net asset growth rate.
Shandong Pharmaceutical Glass Co Ltd Capital Reinvestment Ratio by Year (2001–2025)
Shandong Pharmaceutical Glass Co Ltd capital reinvestment ratio by year from 2001 to 2025. For the full cash flow conversion analysis, see Shandong Pharmaceutical Glass Co Ltd (600529) cash conversion ratio.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.40x | CN¥576.92 Million | CN¥231.86 Million | ▼ -27.7% |
| 2024 | 0.56x | CN¥1.17 Billion | CN¥647.79 Million | ▼ -13.2% |
| 2023 | 0.64x | CN¥1.05 Billion | CN¥671.53 Million | ▼ -77.2% |
| 2022 | 2.82x | CN¥252.44 Million | CN¥710.71 Million | ▲ +161.1% |
| 2021 | 1.08x | CN¥750.44 Million | CN¥809.26 Million | ▲ +14.0% |
| 2020 | 0.95x | CN¥566.01 Million | CN¥535.20 Million | ▼ -4.3% |
| 2019 | 0.99x | CN¥599.05 Million | CN¥591.69 Million | ▲ +32.4% |
| 2018 | 0.75x | CN¥465.77 Million | CN¥347.38 Million | ▲ +83.9% |
| 2017 | 0.41x | CN¥411.96 Million | CN¥167.06 Million | ▲ +4.5% |
| 2016 | 0.39x | CN¥506.53 Million | CN¥196.58 Million | ▼ -2.5% |
| 2015 | 0.40x | CN¥389.63 Million | CN¥155.12 Million | ▼ -20.5% |
| 2014 | 0.50x | CN¥266.63 Million | CN¥133.53 Million | ▼ -10.6% |
| 2013 | 0.56x | CN¥268.60 Million | CN¥150.49 Million | ▼ -86.9% |
| 2012 | 4.28x | CN¥28.52 Million | CN¥122.10 Million | ▲ +440.5% |
| 2011 | 0.79x | CN¥274.63 Million | CN¥217.53 Million | ▼ -14.2% |
| 2010 | 0.92x | CN¥217.01 Million | CN¥200.37 Million | ▲ +94.3% |
| 2009 | 0.48x | CN¥249.27 Million | CN¥118.44 Million | ▼ -72.5% |
| 2008 | 1.73x | CN¥91.76 Million | CN¥158.40 Million | ▲ +31.6% |
| 2007 | 1.31x | CN¥122.63 Million | CN¥160.82 Million | ▲ +45.8% |
| 2006 | 0.90x | CN¥78.47 Million | CN¥70.59 Million | ▼ -53.4% |
| 2005 | 1.93x | CN¥44.09 Million | CN¥85.09 Million | ▼ -57.8% |
| 2003 | 4.58x | CN¥59.35 Million | CN¥271.74 Million | ▲ +344.7% |
| 2002 | 1.03x | CN¥109.26 Million | CN¥112.49 Million | ▲ +16.3% |
| 2001 | 0.89x | CN¥28.60 Million | CN¥25.32 Million | — |